Date: 2011-01-26
Type of information: Distribution agreement
Compound: Removab® (catumaxomab)
Company: Swedish Orphan Biovitrum (Sweden) Fresenius Biotech (Germany)
Therapeutic area: Cancer - Oncology
Type agreement: Distribution
Action mechanism: trifunctional antibody
Disease: malignant ascites in patients with EpCAM (Epithelial Cell Adhesion Molecule) positive carcinomas where standard therapy is not available or no longer feasible.
Details: Fresenius Biotech announced a Removab® distribution agreement with Swedish Orphan Biovitrum (Sobi). Under the seven-year agreement, Sobi will distribute the trifunctional antibody Removab® exclusively in 15 European countries. The markets covered by the agreement include Bulgaria, the Czech Republic, Denmark, Estonia, Finland, Iceland, Latvia, Lithuania, Norway, Poland, Romania, Slovakia, Slovenia and Sweden. Removab® was granted marketing authorization by the European Commission in April 2009 for the treatment of malignant ascites associated with cancer and so far has been launched in Germany, Austria and France. Removab® (catumaxomab) has been developed by the Helmholtz Zentrum München. It had received a favourable opinion in February 2009 for the intraperitoneal treatment of malignant ascites in cancer patients expressing Ep-CAM (epithelial cell adhesion molecule).
Financial terms: Financial terms were not disclosed.
Latest news:
